Lonza

One firm, Exosome Diagnostics, is working to streamline payor coverage for a commercial test, and researchers are simultaneously developing promising ways to isolate exosomes.

The Swiss biopharmaceutical company said it undertook both deals to develop new therapeutic and diagnostic applications based around exosomes.